Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery
Dabigatran etexilate (DE) is a novel oral anticoagulant indicated for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement surgery. The majority of these patients receive some kind of thromboprophylaxis, most commonly low-molecular-weight heparin (LMWH). However, the subcutaneous route of LMWH administration may act as a barrier to the continuation of effective anticoagulant prophylaxis after discharge from hospital. The oral route of DE administration may allow more patients to receive extended thromboprophylaxis and may reduce costs, such as those associated with nurse time for LMWH administrations, platelet monitoring, needlestick injuries and sharps disposal. This article presents an overview of the clinical evidence for DE and a systematic review of the economic evaluations of the drug
Wolowacz, S. (2011). Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert Review of Pharmacoeconomics & Outcomes Research, 11(1), 9-25.